Novartis AG is planning to evaluate its investigational oral spinal muscular atrophy (SMA) drug branaplam as a treatment for Huntington's disease (HD), suggesting that the future prospects for the therapy may be best served by focusing on this other devastating inherited neurodegenerative condition instead.
Branaplam, previously known as LMI070, is a once-weekly, orally administered, small molecule RNA splicing modulator that Novartis has been developing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?